BIEL's relatively new lost cost operating strategy has put the company in position to be profitable soon (if not already) such that:
1) $800k annual revenue is a significant increase from the the $700k-ish reported the previous two years and will get the pps out of the trips;
2) $1.5 million annual revenue (or a $400k quarter) achieves cash flow positive/profitability and gets the pps to copper.
Even the worst, most negative basher I've seen in all of my years following BIEL acknowledges "the company is very close to profitability every quarter. Just a stone's throw, really", and has made numerous statements which support the conclusion that the new low-cost business model will likely lead to profitability, such as:
Positives for BIEL:
1. It's a real company with a real product.
2. The company is not burning $$$ millions every quarter trying to get a product through the FDA wringer. They accomplished that already.
3. The company is very close to profitability every quarter. Just a stone's throw, really.
4. There is no toxic debt. The company is not sinking under death spiral financing.
5. Down here in the world of sub-penny pink biotech, EACH of these is the exception, not the rule. That makes BIEL.... exceptional!
6. Every biotech has an accumulated deficit during their developmental stage. 7. Current burn rate - think about it: $219,999 in 2023 for Other Gen and Admin Expenses -- FOR THE ENTIRE YEAR. That's bare bones.
8. The quote is "they are close to profitability" and it's true -- they are.
9. Expenses are bare bones at $750,000 a year.
10. The common definition of profitability: Net Revenues exceeding Total Gen and Admin expenses. Debt isn't counted, this bare-bones operational level.
11. Yes, "developmental stage" -- most of that $39M accumulated deficit was incurred before 2020. They're no longer increasing that number by $$$ millions per year.
12. Yes, $750,000 per year - those are bare bones expenses for GENERAL AND ADMIN EXPENSES (salaries, utilities, R&D, Advertising, etc).
1) $800k annual revenue is a significant increase from the the $700k-ish reported the previous two years and will get the pps out of the trips;
2) $1.5 million annual revenue (or a $400k quarter) achieves cash flow positive/profitability and gets the pps to copper.
Even the worst, most negative basher I've seen in all of my years following BIEL acknowledges "the company is very close to profitability every quarter. Just a stone's throw, really", and has made numerous statements which support the conclusion that the new low-cost business model will likely lead to profitability, such as:
Positives for BIEL:
1. It's a real company with a real product.
2. The company is not burning $$$ millions every quarter trying to get a product through the FDA wringer. They accomplished that already.
3. The company is very close to profitability every quarter. Just a stone's throw, really.
4. There is no toxic debt. The company is not sinking under death spiral financing.
5. Down here in the world of sub-penny pink biotech, EACH of these is the exception, not the rule. That makes BIEL.... exceptional!
6. Every biotech has an accumulated deficit during their developmental stage. 7. Current burn rate - think about it: $219,999 in 2023 for Other Gen and Admin Expenses -- FOR THE ENTIRE YEAR. That's bare bones.
8. The quote is "they are close to profitability" and it's true -- they are.
9. Expenses are bare bones at $750,000 a year.
10. The common definition of profitability: Net Revenues exceeding Total Gen and Admin expenses. Debt isn't counted, this bare-bones operational level.
11. Yes, "developmental stage" -- most of that $39M accumulated deficit was incurred before 2020. They're no longer increasing that number by $$$ millions per year.
12. Yes, $750,000 per year - those are bare bones expenses for GENERAL AND ADMIN EXPENSES (salaries, utilities, R&D, Advertising, etc).
1
